Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from September 11, 2025

Near target Published before the outcome was known, scored automatically when the window closed on December 10, 2025 — -9.8% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$53.75 – $55.00Entry zone — fair-value band

$54.38Published — price the day we called it

$63.08Target — the price the thesis aimed for

$62.32Peak — highest point inside the window, not a realized return

$49.05Window close — end-of-window price, context only

What happened

Near target

Came within reach: 91% of the predicted growth at its peak, just short of the target.

At window close

-9.8%

realized, from the publication price to the last close inside the window

Peak gain

+14.6%

peak, from the publication price — not a realized return

S&P 500, same window

+4.8%

SPY over the identical days, dividend-adjusted

Window close

$49.05

last close inside the window, ended December 10, 2025

Peak price

$62.32

peak on September 19, 2025 — not a realized return

Days to target

—

The thesis — published September 11, 2025

Predicted growth

+16%

over the measurement window

Target price

$63.08

the price the thesis aimed for

Entry zone

$53.75 – $55.00

the fair-value band we waited for

Price at publication

$54.38

published September 11, 2025

Confidence

66%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Shares fell after headlines about a lawsuit and a possible corporate change, but an independent reviewer said Wegovy and Zepbound are worth the cost, which supports long-term value. The drop looks overdone and early signs suggest buyers may be returning. If the price climbs back above 56-57, we expect a rebound over the next 0-3 months. We will start small and add once the move is confirmed to manage legal and budget risks.

Primary drivers

Leader in weight-loss and diabetes drugs with strong, growing demand
Price fell hard recently; early signs buyers are stepping back in
Recent negative headlines pushed shares down, creating a potential entry
Court cases and healthcare budget limits could weigh on future growth

How it played out

NVO: rebound peaked below the target

Lyra published NVO at 54.38 on 2025-09-11, with 16% expected growth over the short term. The thesis pointed to weight-loss and diabetes drug demand, a recent price drop, signs that buyers may have been returning, and risks from court cases and healthcare budget limits.

Inside the window from 2025-09-11 to 2025-12-10, NVO rose to a peak of 62.32 on 2025-09-19, a 14.6% gain. It stayed below the 63.08 target. It ended at 49.05. The thesis partly played out: the rebound came quickly, but it never got there and did not hold.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals